Canaccord’s Neil Maruoka jumps up his price target on VRX, but even with more optimism, still angles for 5% downside potential from the stock.
Salix Pharmaceuticals, a wholly owned subsidiary of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), announced today that the U.S.
Goldman Sachs’ Dana Flanders sheds new insights on Valeant from a bearish standpoint, spotting 5% in loss potential for the stock.
Cantor’s Louise Chen dismisses Valeant share weakness today, making a bullish case that the majority of Xifaxan’s sales stem from IBS-D; not Traveler’s Diarrhea.
H.C.
BTIG’s Tim Chiang notes that with various positives soaring in Valeant’s favor, these are mostly reflected in the stock’s recently climbing levels.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced this morning that its subsidiary Bausch + Lomb has received CE Mark from the European Commission for the …
Cantor’s Louise Chen: Valeant will look more interesting as long-term investment.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and its team are raring to continue the rebounding recovery of the once beleaguered biotech giant, and for …
Cantor’s Louise Chen believes Valeant will surpass $8 billion in sales in 2018, and says the set-up for the rebounding giant “keeps getting better” following Lumify’s approval.
